ATE393625T1 - Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen - Google Patents

Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen

Info

Publication number
ATE393625T1
ATE393625T1 AT04740032T AT04740032T ATE393625T1 AT E393625 T1 ATE393625 T1 AT E393625T1 AT 04740032 T AT04740032 T AT 04740032T AT 04740032 T AT04740032 T AT 04740032T AT E393625 T1 ATE393625 T1 AT E393625T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
hydroxy tamoxifen
excessive scaring
excessive
Prior art date
Application number
AT04740032T
Other languages
English (en)
Inventor
Andrew Palumbo
Julius Few
Dana Hilt
Original Assignee
Ascend Therapeutics Inc
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascend Therapeutics Inc, Univ Northwestern filed Critical Ascend Therapeutics Inc
Application granted granted Critical
Publication of ATE393625T1 publication Critical patent/ATE393625T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04740032T 2003-06-09 2004-06-02 Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen ATE393625T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47661803P 2003-06-09 2003-06-09

Publications (1)

Publication Number Publication Date
ATE393625T1 true ATE393625T1 (de) 2008-05-15

Family

ID=33551623

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740032T ATE393625T1 (de) 2003-06-09 2004-06-02 Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen

Country Status (12)

Country Link
US (1) US7767717B2 (de)
EP (1) EP1631275B1 (de)
JP (1) JP4682129B2 (de)
AT (1) ATE393625T1 (de)
AU (1) AU2004246812B8 (de)
CA (1) CA2528431C (de)
DE (1) DE602004013439T2 (de)
DK (1) DK1631275T3 (de)
ES (1) ES2304610T3 (de)
NZ (1) NZ544031A (de)
PT (1) PT1631275E (de)
WO (1) WO2004110420A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263072T3 (es) * 2002-12-18 2006-12-01 Laboratoires Besins International Tratamiento de la mastalgia con 4-hidroxi tamoxifeno.
WO2004054558A2 (en) 2002-12-18 2004-07-01 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
ES2456958T3 (es) * 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
ATE401067T1 (de) * 2003-12-15 2008-08-15 Besins Int Lab Verwendung von 4-hydroxytamoxifen zur herstellung eines medikaments zur behandlung von gynäkomastie
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (de) * 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.
JP5189093B2 (ja) * 2006-07-31 2013-04-24 ラボラトワール・ベザン・ザンテルナショナル 過剰瘢痕化の治療および予防
EP1891945A1 (de) * 2006-07-31 2008-02-27 Laboratoires Besins International Behandlung und Prävention von übermässiger Narbenbildung
AU2008343755A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
EP2252690A2 (de) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Verwendung von anti-connexin-43-polynukleotiden zur behandlung abnormaler oder übermässiger narben
US20140350117A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Topical Scar Treatment Composition and Method of Using Same
US20140350106A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same
US20210015905A1 (en) * 2017-09-01 2021-01-21 Excel Med, Llc Pharmaceutical composition for treating keloid and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP0287690B1 (de) 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
JP3149180B2 (ja) * 1989-07-31 2001-03-26 マサチユセツツ・インスチチユート・オブ・テクノロジー 瘢痕治療のためのカルシウム拮抗薬の使用
TW218849B (de) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
WO1994002130A1 (en) * 1992-07-20 1994-02-03 Massachusetts Institute Of Technology Control of wound scar production with calcium antagonists alone or in a combination with a steroid
US5552162A (en) 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
EP1043986B1 (de) * 1997-12-23 2003-04-16 Hexal Ag Gemisch und pharmazeutische zubereitung enthaltend z-4-hydroxytamoxifen und cyclodextrin
US6013270A (en) 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE60139625D1 (de) 2001-12-07 2009-10-01 Besins Int Belgique Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung
ES2263072T3 (es) 2002-12-18 2006-12-01 Laboratoires Besins International Tratamiento de la mastalgia con 4-hidroxi tamoxifeno.
WO2004054558A2 (en) 2002-12-18 2004-07-01 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
ES2456958T3 (es) 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (de) 2004-03-22 2005-09-28 Laboratoires Besins International 4-Hydroxytamoxifen zur Behandlung von benignen Brusterkrankungen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (de) 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.

Also Published As

Publication number Publication date
PT1631275E (pt) 2008-08-04
US7767717B2 (en) 2010-08-03
DK1631275T3 (da) 2008-08-18
JP2006527234A (ja) 2006-11-30
WO2004110420A1 (en) 2004-12-23
ES2304610T3 (es) 2008-10-16
DE602004013439T2 (de) 2009-06-04
JP4682129B2 (ja) 2011-05-11
DE602004013439D1 (de) 2008-06-12
EP1631275B1 (de) 2008-04-30
WO2004110420A8 (en) 2005-11-24
AU2004246812A1 (en) 2004-12-23
CA2528431A1 (en) 2004-12-23
HK1082203A1 (en) 2006-06-02
AU2004246812B8 (en) 2010-01-14
NZ544031A (en) 2008-08-29
CA2528431C (en) 2012-09-18
EP1631275A1 (de) 2006-03-08
US20050032910A1 (en) 2005-02-10
AU2004246812B2 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
ATE393625T1 (de) Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
ATE526959T1 (de) Behandlung von muskelschwund mit selektiven androgenrezeptormodulatoren
ATE316786T1 (de) Behandlung von mukositis
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
DE60101265D1 (de) Behandlung von augenschmerzen
ATE460164T1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200971053A1 (ru) Способы лечения кожных язв
DE602005025517D1 (de) Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
BR0312597A (pt) Combinações de drogas para o tratamento de neoplasmas
DE602004003587D1 (de) Kosmetische verwendung einer zusammensetzung mit mindestens einem oxazolin als wirkstoff, als abnehmprodukt und/oder zur prävention und/oder behandlung von cellulite
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
DE60212613D1 (de) Doxycyclin zur behandlung von akne
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE602004011055D1 (de) Präoperative behandlung von postoperativen schmerzen
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
DE602004016126D1 (de) Aplidine zur behandlung von multiplem myelom
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1631275

Country of ref document: EP